Fennec Pharmaceuticals (FENC) Asset Writedowns and Impairment (2024 - 2025)
Fennec Pharmaceuticals' (FENC) quarterly Asset Writedowns and Impairment came in at $1.3 million in Q4 2025, up 174.18% on a QoQ basis from -$1.7 million in Q3 2025.
Powered by 
Analysis
Fennec Pharmaceuticals (FENC) Asset Writedowns and Impairment (2024 - 2025) Analysis & Trends
Fennec Pharmaceuticals (FENC) has 1 years of Asset Writedowns and Impairment data on file, last reported at $1.3 million in Q4 2025.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $773000.0 (changed N/A YoY) and the FY2025 annual result came in at $773000.0, up 49.52% from the prior year.
- Asset Writedowns and Impairment grew to $1.3 million in Q4 2025, from -$1.7 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $1.3 million in Q4 2025 to a low of -$1.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Fennec Pharmaceuticals | 432.85 Mn | 391.60 Mn | 17.15 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 2.62 Mn |
| Sep 30, 2025 | -1.74 Mn |
| Jun 30, 2025 | 1.14 Mn |
| Mar 31, 2025 | 79,000.00 |
| Dec 31, 2024 | 199,000.00 |